-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 14, aTyr Pharma announced that the U.
Systemic sclerosis is a chronic progressive autoimmune disease characterized by inflammation and fibrosis of connective tissue throughout the body, including the skin and other internal organs
The pathogenesis of SSc-ILD is driven by the same immune cells that play a central role in the pathology of pulmonary sarcoidosis, and neuroprotin-2 (NRP2) on these cells is upregulated
In animal models of SSc and idiopathic pulmonary fibrosis, efzofitimod has been shown to reduce lung and skin fibrosis, with efficacy comparable to or better than known antifibrosis drugs, including nidanibu and pirfenidone
The main indication developed by aTyr for efzofitimod is pulmonary sarcoidosis, a major type